347 related articles for article (PubMed ID: 29430814)
1. SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?
Khouri C; Cracowski JL; Roustit M
Diabetes Obes Metab; 2018 Jun; 20(6):1531-1534. PubMed ID: 29430814
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
[TBL] [Abstract][Full Text] [Related]
4. Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio.
Kaneko M; Narukawa M
Clin Drug Investig; 2019 Feb; 39(2):179-186. PubMed ID: 30506378
[TBL] [Abstract][Full Text] [Related]
5. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study.
Ueda P; Svanström H; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Pasternak B
BMJ; 2018 Nov; 363():k4365. PubMed ID: 30429124
[TBL] [Abstract][Full Text] [Related]
6. Peripheral artery disease and amputations with Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials.
Dicembrini I; Tomberli B; Nreu B; Baldereschi GI; Fanelli F; Mannucci E; Monami M
Diabetes Res Clin Pract; 2019 Jul; 153():138-144. PubMed ID: 31150722
[TBL] [Abstract][Full Text] [Related]
7. Risk of amputations associated with SGLT2 inhibitors compared to DPP-4 inhibitors: A propensity-matched cohort study.
Adimadhyam S; Lee TA; Calip GS; Smith Marsh DE; Layden BT; Schumock GT
Diabetes Obes Metab; 2018 Dec; 20(12):2792-2799. PubMed ID: 29971914
[TBL] [Abstract][Full Text] [Related]
8. Impact of SGLT Inhibitors on Multiple Organ Defects in Diabetes.
Asrih M; Gariani K
Curr Diabetes Rev; 2020; 16(5):411-418. PubMed ID: 31702506
[TBL] [Abstract][Full Text] [Related]
9. An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors.
Lamos EM; Hedrington M; Davis SN
Expert Opin Drug Saf; 2019 Aug; 18(8):691-701. PubMed ID: 31150300
[TBL] [Abstract][Full Text] [Related]
10. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
Misher A; Ampuero A; Phan R; Aziz S; Ebong E; Braich J; Dyches K; Southwood R
Am J Ther; 2020 Mar; 28(1):e96-e110. PubMed ID: 32384319
[TBL] [Abstract][Full Text] [Related]
11. The effect of SGLT2 inhibitors on cardiovascular events and renal function.
Imprialos KP; Stavropoulos K; Doumas M; Karagiannis A; Athyros VG
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1251-1261. PubMed ID: 28829209
[TBL] [Abstract][Full Text] [Related]
12. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
Chang HY; Singh S; Mansour O; Baksh S; Alexander GC
JAMA Intern Med; 2018 Sep; 178(9):1190-1198. PubMed ID: 30105373
[TBL] [Abstract][Full Text] [Related]
13. SGLT-2 Inhibitors: A Novel Mechanism in Targeting Glycemic Control in Type 2 Diabetes Mellitus.
Nathan KT; Ahmed-Sarwar N; Werner P
Consult Pharm; 2016 May; 31(5):251-60. PubMed ID: 27178654
[TBL] [Abstract][Full Text] [Related]
14. In brief: Canagliflozin and lower limb amputations.
Med Lett Drugs Ther; 2020 Sep; 62(1607):152. PubMed ID: 32960870
[No Abstract] [Full Text] [Related]
15. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
16. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
Ghosh A; Gupta R; Misra A
J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
[No Abstract] [Full Text] [Related]
17. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
Paul SK; Bhatt DL; Montvida O
Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
[TBL] [Abstract][Full Text] [Related]
18. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.
Yuan Z; DeFalco FJ; Ryan PB; Schuemie MJ; Stang PE; Berlin JA; Desai M; Rosenthal N
Diabetes Obes Metab; 2018 Mar; 20(3):582-589. PubMed ID: 28898514
[TBL] [Abstract][Full Text] [Related]
19. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.
Riser Taylor S; Harris KB
Pharmacotherapy; 2013 Sep; 33(9):984-99. PubMed ID: 23744749
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals.
Huang CY; Lee JK
Diabetes Obes Metab; 2020 Dec; 22(12):2348-2355. PubMed ID: 32744411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
